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Purpose: Evidence suggests that clinical outcomes
for people with type 2 diabetes mellitus can be
improved through multifactorial treatment. The key
challenges in the successful treatment of type 2
diabetes include maintaining tight glycemic control,
minimizing the risk of hypoglycemia, controlling
cardiovascular risk factors, and reducing or control-
ling weight. The aim of the present analysis was to
evaluate the cost per patient achieving a composite
clinical end point (glycosylated hemoglobin o7%,
with no weight gain and no hypoglycemic events) in
patients with type 2 diabetes in Quebec, Quebec,
Canada, receiving liraglutide 1.2 mg, liraglutide
1.8 mg, thiazolidinedione, sulfonylurea, insulin glar-
gine, sitagliptin, or exenatide.
Methods: The proportion of patients achieving
control was taken from a meta-analysis that was
based on the Phase III trial program of liraglutide.
Treatment costs, estimated from a health care payer
perspective, were calculated on the basis of the trials
included in the meta-analysis and captured the study
drug, needles, self-monitoring of blood glucose
(SMBG) test strips, SMBG lancets, and other antidia-
betes medications received. Cost-effectiveness in terms
of cost per patient achieving the composite end point
(cost of control) was evaluated with an economic
model developed in Microsoft Excel. No discounting
was applied to cost or clinical outcomes because these
were not projected beyond a 1-year time horizon.
Sensitivity analyses were performed.
Findings: Liraglutide 1.8 mg was associated with
the lowest number needed to treat, with 3 patients
needing to be treated to bring 1 patient to the
composite end point. Pioglitazone was associated with
the highest number needed to treat, with 17 patients
requiring treatment to bring 1 patient to the composite
end point. Evaluation of only annual pharmacy costsAugust 2015indicated that liraglutide 1.8 mg was the most costly
treatment at Can$2780 per patient per year. Pioglita-
zone and glimepiride were associated with the lowest
direct annual costs. Combining the clinical efﬁcacy
data with the annual cost of medications produced
cost of control values of Can$6070 (liraglutide
1.2 mg), Can$6949 (liraglutide 1.8 mg), Can$7237
(glimepiride), Can$7704 (exenatide), Can$8297
(insulin glargine), Can$8741 (pioglitazone), and Can
$9270 (sitagliptin) per patient achieving the composite
end point.
Implications: Liraglutide 1.2 mg and 1.8 mg were
associated with the lowest cost of control values,
driven by the high proportion of patients achieving
the composite end point, which offset the higher
medication costs. A relatively low cost of control
value was achieved for glimepiride, driven by low
acquisition costs, despite relatively few patients
achieving the composite end point. (Clin Ther.
2015;37:1677–1688) & 2015 The Authors. Published
by Elsevier HS Journals, Inc.
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mellitus, liraglutide, Quebec.INTRODUCTION
It is well established that diabetes mellitus represents
one of the most relevant challenges facing health care
systems around the world.1 Global estimates suggest
that the worldwide prevalence of the disease (including
type 1 and type 2 diabetes, of which type 2 is the most
prevalent) is 8.3%, and this is projected to increase to1677
Clinical Therapeutics10.1% by 2035.2 A recent study by Greiver et al3
estimated the prevalence of diabetes in Canada to be
slightly below the worldwide prevalence, at 7.6%,
whereas the disease is associated with 417,000
deaths per year.2 In addition to the substantial clinical
burden, the Canadian Diabetes Association reported
that the economic burden of diabetes in Canada was
Can$12.2 billion in 2010, increasing from Can
$6.3 billion in 2000 and estimated that the cost
would rise to Can$16.9 billion by 2020.4
Traditionally, therapy for people with type 2 diabetes
has focused on maintaining glycemic control, but it is
widely accepted that patients beneﬁt from a multi-
factorial approach to disease management. This was
reported in the Steno-2 study, which compared conven-
tional treatment for multiple risk factors with intensive
multifactorial treatment.5–7 The key challenges in the
successful treatment of type 2 diabetes include main-
taining tight glycemic control, minimizing the risk of
hypoglycemia, controlling cardiovascular risk factors
such as blood pressure and serum lipid concentrations,
and reducing or controlling weight. Most long-
established diabetes interventions are designed to im-
prove glycemic control, but they do little to address
other risk factors and meet the multifaceted needs of the
patient with type 2 diabetes.8
Recently released treatment guidelines now include
recommendations that address not only glycemic
targets but also a range of other treatment goals.
Guidelines released by the Canadian Diabetes Associ-
ation in 2013 recommend a glycosylated hemoglobin
(HbA1c) target of o7% for most patients.9 However,
this target may be raised or lowered slightly,
depending on the patient, to produce an indivi-
dualized treatment target. A systolic blood pressure
target of o130 mm Hg and LDL cholesterol target of
o2 mmol/L are recommended.10,11 The guidelines
also state that, when a diabetes medication is being
chosen, the potential impact on weight and risk of
hypoglycemia should be considered.12,13 These multi-
dimensional treatment goals are also reﬂected in other
guidelines, such as goals released by the American
Diabetes Association and the European Association
for the Study of Diabetes.8,14
In 2011, Zinman et al15 published a meta-analysis
that evaluated the proportion of patients who
achieved the composite end point of HbA1c o7%,
with no weight gain and no hypoglycemic events,
based on the Phase III trial program of liraglutide1678(a glucagonlike hormone peptide-1 receptor agonist).
This end point was chosen because it represents a
clinically relevant outcome, reﬂecting the multifaceted
treatment targets for patients with type 2 diabetes
mellitus, and was a predeﬁned secondary end point in
the liraglutide trial program. The aim of the present
analysis was to evaluate, using a simple and trans-
parent economic model, the mean cost per patient
who achieved the composite clinical end point (cost of
control) in patients with type 2 diabetes in Quebec,
Canada, who received liraglutide, thiazolidinedione,
sulfonylurea, insulin glargine, sitagliptin, or exenatide,
based on the meta-analysis of Zinman et al.15
METHODS
Clinical Data
The proportion of patients who achieved control
was taken from a meta-analysis based on the Phase III
trial program of liraglutide that assessed the propor-
tion of patients who achieved the composite clinical
end point of HbA1c o7%, with no weight gain and
no hypoglycemic events.15 The study took data from
7 clinical trials in patients with type 2 diabetes,
comparing the efﬁcacy and safety proﬁle of
liraglutide in combination with placebo, metformin,
sulfonylurea, or thiazolidinedione and compared with
placebo, thiazolidinedione, sulfonylurea, insulin
glargine, exenatide, or sitagliptin, with a total of
4625 patients included. All data were based on the
results at 26 weeks, even if the trial extended for a
longer period. The detailed methodology was
described previously.15 Brieﬂy, change in HbA1c and
weight were both analyzed by an ANCOVA with
previous treatment (combination or monotherapy) and
randomized treatment as ﬁxed effects and baseline values
of HbA1c and weight as covariates. Weight gain was
deﬁned as any positive change in weight for an
individual patient at 26 weeks. Hypoglycemic episodes
were deﬁned as any subject-reported episode over the
26-week period and were considered major if the subject
was not able to self-treat.
This meta-analysis found that a greater proportion
of patients who received liraglutide, either 1.2 mg or
1.8 mg, achieved the composite clinical end point of
HbA1c o7% without weight gain or hypoglycemia
(Figure 1); that is, a greater proportion of patients
who received liraglutide achieved control. The odds
ratio for achieving control favored liraglutide 1.8 mg
over the other therapies (10.5 vs thiazolidinedione,Volume 37 Number 8
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Figure 1. Percentage of patients achieving the composite end point of glycosylated hemoglobino 7% with no
weight gain and no hypoglycemic events.
R. Skovgaard et al.7.4 vs sulfonylurea, 3.7 vs insulin glargine, 5.2 vs
sitagliptin, and 2.0 vs exenatide; all P o 0.01). This
was also the case for liraglutide 1.2 mg versus most
therapies (7.4 vs thiazolidinedione, 5.2 vs sulfonylurea,
3.7 vs sitagliptin; all Po 0.01), although the odds ratios
versus insulin glargine and exenatide were not statistically
signiﬁcantly different from 1.Cost Data
Costs were estimated from a health care payer
perspective in Quebec, Quebec, Canada. Pharmacy
costs were taken from the List of Medications released
by the Régie de l’assurance maladie Quebec, because
this represents a regulatory list of the medications
covered by Quebec's basic prescription drug insurance
plan.16 Within the Canadian health care system,
acquisition costs of drugs and medical consumables
differ from province to province. For the present
analysis, costs were based on Quebec because costs
are published and not expected to change in the near
future. However, the costs used in the present analysis
are likely to only have small variation across the
Canadian provinces; therefore, the results are likely to
be generalizable to the Canadian setting as a whole.
Mean daily per patient costs of treatment were
calculated on the basis of the trials included in the
meta-analysis and captured the study drug (liraglutide,
pioglitazone, glimepiride, insulin glargine, sitagliptin,August 2015or exenatide), needles (for subcutaneous injection
when applicable), self-monitoring of blood glucose
(SMBG) test strips, SMBG lancets, and other antidia-
betes medications received (such as metformin or
glimepiride when applicable, based on the trials
included in the meta-analysis). Doses received were
based on the mean dose received in the trial. Patients
were assumed to require no SMBG testing when
receiving incretin therapy (liraglutide, exenatide, and
sitagliptin) or pioglitazone and once-daily testing
when receiving glimepiride or insulin glargine. When
an intervention was included in 41 of the trials
(liraglutide 1.2 mg, liraglutide 1.8 mg, and glimepir-
ide), an average cost was taken to ensure that the cost
used in the analysis was representative (note that a
weighted average was not taken because this would
have reﬂected the recruitment in each trial, rather than
the proportion of patients who received medications
in clinical practice). Annual costs were estimated by
multiplying the daily cost by 365 (Table I). All costs
were reported in 2014 Canadian dollars (Can$).Evaluation of Cost-Effectiveness
Cost-effectiveness in terms of cost per patient who
achieved the composite end point (cost of control) was
evaluated with an economic model developed in Excel
(Microsoft, Redman, Wash). The model calculated
the cost of control by dividing the annual cost of1679
Table I. Mean annual pharmacy costs.
Treatment Pack contents Pack price, Can$ Annual cost, Can$
Liraglutide 1.2 mg 36 mg 136.98 1942.41
Liraglutide 1.8 mg 54 mg 205.47 2779.65
Thiazolidinedione (pioglitazone) 100  30-mg tablet 70.00 524.49
Sulfonylurea (glimepiride) 30  4- mg tablet 23.21 578.99
Insulin glargine 1500 IU 88.12 1244.52
Sitagliptin 30  100-mg tablet 78.53 1019.74
Exenatide 300 mg 137.70 1926.03
Pharmacy cost were taken from the List of Medications released by the Régie de l’assurance maladie Quebec.16 Annual per
patient costs of treatment captured the study drug, needles, SMBG test strips, SMBG lancets, and other antidiabetes
mediations received (such as metformin or glimepiride).
Can$ ¼ 2014 Canadian dollars; SMBG, self-monitoring of blood glucose.
Clinical Therapeuticstreatment by the proportion of patients who achieved
control. Cost of control was calculated for patients
who received treatment with liraglutide 1.2 mg,
liraglutide 1.8 mg, pioglitazone, glimepiride, insulin
glargine, sitagliptin, or exenatide. No discounting was
applied because outcomes were not projected beyond
a 1-year time horizon. A worked example of the
calculation of the cost of control for liraglutide
1.2 mg versus sitagliptin is shown in Table II.
Sensitivity Analyses
Sensitivity analyses were performed to investigate
the effects of variation in input data on the cost of
control. In separate sensitivity analyses the cost
parameters, speciﬁcally drug acquisition costs, needle
costs, and costs associated with SMBG, were in-
creased and decreased by 20%. The percentage of
patients who reached the composite end point in all
treatment arms was varied by 20% in 1 sensitivity
analysis to evaluate the impact of bringing a greater or
lesser proportion of patients to target.
A probabilistic sensitivity analysis (PSA) with
simultaneous variation in modeling parameters
was also conducted. However, the meta-analysis
on which the modeling analysis was based did not
report any measure of uncertainty around the
proportion of patients who achieved the composite
end point of HbA1c o7% with no weight gain and
no hypoglycemic events.15 This data would ideally
be used to prepare a probabilistic analysis.
However, the data within the meta-analysis allowed1680calculation of odds ratios (with 95% CIs) of achiev-
ing control with alternative therapy options versus
liraglutide 1.2 mg. In the PSA, the proportion of
patients who achieved control with liraglutide
1.2 mg was ﬁxed at the base case value, with the
proportion of patients who achieved control in the
other treatment arms calculated on the basis of an
odds ratio, sampled from a normal distribution.
Costs were sampled from normal distributions in all
treatment arms. When mean costs were calculated
by averaging costs from a number of trials (liraglu-
tide 1.2 mg, liraglutide 1.8 mg, and glimepiride), the
SE was calculated to inform the measure of spread
of the normal distribution. When treatment costs
were based on only 1 study, the SE was assumed to
be 10% of the total cost. A total of 1000 calcu-
lations were made (because results were stable at
this number of iterations), with the proportion of
patients who achieved control and annual treatment
cost sampled between each calculation. Across each
iteration the therapy with the lowest cost of control
was recorded.
Furthermore, 2 additional analyses were performed
to investigate the effect of varying the composite end
point. An analysis in which the cost per patient who
achieved an HbA1c o7% was examined, as was a
scenario in which the composite end point was
changed to HbA1c o7% and systolic blood pres-
sure o130 mm Hg. These alternative end points were
chosen because they reﬂect treatment guidelines within
the Canadian setting.9,11Volume 37 Number 8
Table II. Worked example of cost of control calculation for liraglutide 1.2 mg versus sitagliptin.
Liraglutide
1.2 mg Sitagliptin Interpretation
Annual drug cost, Can$ 1942.41 1019.74
Drug cost index 190.48 Liraglutide is almost twice as costly
as sitagliptin on an annual per
patient basis
Drug efﬁcacy, % of patients
achieving control
32 11
Drug efﬁcacy index 290.91 Liraglutide is almost 3 times as
effective as sitagliptin in terms
of bringing patients to target
Cost per patient achieving control,
Can$
6070 9270
Cost of control index, Can$ 65.48 Liraglutide costs approximately
two-thirds of the amount of
sitagliptin to achieve a similar
outcome
Amount spent to achieve target
relative to Can$1 spent on
liraglutide, Can$
1.53 For every Can$1 spent on
liraglutide Can$1.56 must be
spent on sitagliptin to bring the
same 1 patient to control
Cost of control was deﬁned as the mean cost of treatment to bring 1 patient to the composite end point of glycosylated
hemoglobin o 7%, with no weight gain and no hypoglycemic events.
Can$ ¼ 2014 Canadian dollars.
R. Skovgaard et al.RESULTS
Base Case Analysis
The meta-analysis found that liraglutide 1.8 mg was
the most effective, with 40% of patients achieving the
composite end point. Liraglutide 1.2 mg (32%), exena-
tide (25%), and insulin glargine were the next most-
effective treatments (Figure 1). Pioglitazone (6%),
glimepiride (8%), and sitagliptin (11%) were the least-
effective treatments. On the basis of these values,
liraglutide 1.8 mg was associated with the lowest number
needed to treat, with 3 (rounded up from 2.5) patients
needing to be treated to bring 1 patient to the composite
end point (Figure 2), although liraglutide 1.2 mg and
exenatide were also associated with a low number
needed to treat at 4 (rounded up from 3.1) and 4.0
(no rounding) patients, respectively. Pioglitazone was
associated with the highest number needed to treat to
bring 1 patient to control, 14 patients more than
liraglutide 1.8 mg and 13 patients more than liraglutideAugust 20151.2 mg. Evaluation of direct annual antihyperglycemia
medication costs indicated that liraglutide 1.8 mg was the
most costly treatment at Can$2780 per patient per year
(Table I.). Exenatide and liraglutide 1.2 mg were found
to be the next most costly medications at Can$1926 and
Can$1942 per patient per year, respectively. Pioglitazone
and glimepiride were associated with the lowest annual
costs at Can$525 and Can$579, respectively. Sitagliptin
and insulin glargine were found to have intermediate
costs, with both being slightly under Can$1000 per
patient per year.
Combining the clinical efﬁcacy data on the pro-
portion of patients who achieved control with the
annual cost of medications found that liraglutide
1.2 mg and liraglutide 1.8 mg were associated with
the lowest cost of control at Can$6070 and Can
$6949 per successfully treated patient, respectively
(Figure 3). For these medications, the higher
acquisition costs were offset by the high proportion1681
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Figure 2. Number needed to treat to bring 1 patient successfully to the composite end point of glycosylated
hemoglobin o7.0%, no hypoglycemia, and no weight gain. Blue bars show the value calculated by
the modeling analysis, with red bars showing rounding up to the next integer value.
Clinical Therapeuticsof patients who achieved the composite end point to
produce a low cost of control. Glimepiride was
associated with the next lowest cost of control at
Can$7237 per patient who reached the composite end
point. This was achieved predominantly because of
the low drug acquisition cost because relatively few
patients (8%) achieved the composite clinical end
point. Exenatide, insulin glargine, pioglitazone, and
sitagliptin were associated with cost of control values
of Can$7704, Can$8297, Can$8741, and Can$9270
per successfully treated patient, respectively.
Relative to spending Can$1 on liraglutide 1.2 mg,
achieving the equivalent outcome of bringing 1 patient
to control required spending Can$1.14 with liraglu-
tide 1.8 mg, Can$1.19 with glimepiride, and Can
$1.53 with sitagliptin, with all other values falling
between these (Figure 4). Comparison with liraglutide
1.8 mg found a similar pattern, with relative
expenditure varying from Can$1.04 with glimepiride
to Can$1.33 with sitagliptin.
Sensitivity Analyses
Sensitivity analyses found that reducing the pro-
portion of patients who achieved the composite end
point by 20% had the most relevant impact on the
cost of control (Table III). The cost per patient who
achieved the composite end point was increased by
Can$2318 in the sitagliptin arm, Can$2185 in the1682pioglitazone arm, and Can$2074 in the insulin
glargine arm. Smaller increases were observed in the
liraglutide 1.2 mg, liraglutide 1.8 mg, exenatide, and
glimepiride arms. Increasing the proportion of
patients who achieved the composite end point by
20% had the converse effect, with the cost of control
reduced in all treatment arms.
Variation in drug acquisition costs also had a large
effect on the calculated cost of control for all inter-
ventions. Increasing the pharmacy costs associated
with the study medications resulted in increases in
the costs of control between Can$1136 (for liraglutide
1.2 mg) and Can$1854 (for sitagliptin). Reducing
pharmacy costs had the converse effect. Increasing
or decreasing the cost of needles only affected the cost
of control for injectable medications (liraglutide
1.2 mg, liraglutide 1.8 mg, insulin glargine, and
exenatide). The largest change was seen in the exena-
tide arm, likely because this medication requires twice
daily injection. Similarly, altering the cost of SMBG
testing only affected the cost of control in the
glimepiride and insulin glargine arms.
The PSA suggested that liraglutide 1.2 mg was the
therapy most likely to be associated with the lowest
cost of control. Across the PSA, with the proportion
of patients who reached target and the mean cost
of treatment sampled between recalculation, liraglu-
tide 1.2 mg was associated with the lowest cost perVolume 37 Number 8
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Figure 3. Cost per patient who achieved the composite end point of glycosylated hemoglobin o7.0%, no
hypoglycemia, and no weight gain. Can$ ¼ 2014 Canadian dollars.
R. Skovgaard et al.patient who achieved the composite end point 79%
of the time. Sulfonylurea was the second most likely
treatment to be associated with the lowest cost of
control, being the most cost-effective in 16% of
analyses.
When the analysis considered HbA1c only, it was
found that a greater proportion of patients who1.44
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Figure 4. Amount spent on comparator to bring 1 patie
Can$ ¼ 2014 Canadian dollars.
August 2015achieved the target than in the base case analysis by
using the composite end point in all treatment arms
(Table IV). Liraglutide 1.8 mg and liraglutide 1.2 mg
were associated with the highest proportion of
patients who met the target, at 65% and 56%,
respectively. A lower cost of control was identiﬁed
for all interventions, compared with the base case1.53
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1.11
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Relative to
liraglutide 1.2 mg
Relative to
liraglutide 1.8 mg
nt to control, relative to Can$1 spent on liraglutide.
1683
Table III. Sensitivity analyses. Data are given in 2014 Canadian dollars.
Cost per patient successfully treated to the target composite end point
Liraglutide
1.2 mg
Liraglutide
1.8 mg Pioglitazone Glimepiride
Insulin
glargine Sitagliptin Exenatide
Base case 6070 6949 8741 7237 8297 9270 7704
Variation in cost inputs
Drug acquisition costs
þ20%
7206 8276 10,490 8403 9439 11,124 9044
Drug acquisition
costs –20%
4934 5622 6993 6071 7155 7416 6364
Needle costs þ20% 6148 7012 8741 7237 8464 9270 7905
Needle costs –20% 5992 6886 8741 7237 8130 9270 7504
SMBG costs þ20% 6070 6949 8741 7519 8647 9270 7704
SMBG costs –20% 6070 6949 8741 6956 7947 9270 7704
Variation in clinical inputs
Proportion of patients
meeting target
increased by 20%
5058 5791 7285 6031 6914 7725 6420
Proportion of patients
meeting target
decreased by 20%
7588 8686 10,927 9047 10,371 11,588 9630
SMBG ¼ self-monitoring of blood glucose.
Clinical Therapeuticsanalysis. Cost per successfully treated patient was
lowest for glimepiride at Can$1206 and highest for
exenatide at Can$4280. However, this analysis takes
a glucocentric approach and does not take into
account the importance of bringing patients to
multiple treatment targets. Analysis of the alternative
composite end point of HbA1c o7% and systolic
blood pressure o130 mm Hg (Table IV) found
liraglutide 1.8 mg was the most-effective treatment
(32% of patients achieved the target), followed by
liraglutide 1.2 mg (associated with 29% of patients
meeting the target). Sitagliptin was found to be the
least effective with only 11% of patients achieving the
target. Despite only 18% and 16%, respectively, of
patients meeting the target, glimepiride and pioglita-
zone were associated with the lowest cost of control,
driven by the low acquisition costs of these medica-
tions. Sitagliptin and exenatide were associated with
the highest cost per patient who achieved target, at
Can$9355 and Can$10,411 per successfully treated
patient, respectively.1684Discussion
The present analysis, based on a meta-analysis of
7 clinical trials, calculated the cost of bringing patients
to a clinically relevant composite end point of HbA1c
o7% with no weight gain and no hypoglycemic
events.15 The meta-analysis suggests that a greater
proportion of patients achieve this composite end
point with liraglutide 1.8 mg and liraglutide 1.2 mg
than with glimepiride, pioglitazone, sitagliptin, insulin
glargine, or exenatide. This greater clinical efﬁcacy
resulted in a lower cost per patient who achieved the
composite end point with liraglutide 1.2 mg and
liraglutide 1.8 mg than with other therapy options.
The present analysis suggests that, for patients with
type 2 diabetes in Quebec, Quebec, Canada, greater
clinical efﬁcacy can be achieved with liraglutide
therapy than with other therapy options, and the cost
per patient who achieved a multifaceted treatment
target is likely to be acceptable from a health care
payer perspective. When alternative treatment targets
were considered in sensitivity analyses, the treatmentVolume 37 Number 8
Table IV. Analyses of alternative end points at 26 weeks.
Liraglutide
1.2 mg
Liraglutide
1.8 mg Pioglitazone Glimepiride
Insulin
glargine Sitagliptin Exenatide
HbA1c o7%
Patients reaching target, % 56 65 34 48 53 30 45
Cost per patient treated to
target, Can$
3469 4276 1543 1206 2348 3399 4280
HbA1c o7%, and systolic
blood pressure o130
mm Hg
Patients reaching target, % 29 32 16 18 19 11 19
Cost per patient treated to
target, Can$
6815 8686 3238 3217 6655 9355 10,411
Can$, 2014 Canadian dollars; HbA1c, glycosylated hemoglobin.
R. Skovgaard et al.with the lowest cost per patient who achieved the end
point varied. This was particularly evident when cost
per patient who achieved a target of HbA1co7% was
evaluated. This indicates that, although the long-
standing therapies are associated with good glycemic
control, they do not represent a multifactorial treat-
ment for patients with type 2 diabetes.
It is clear that a multifaceted approach to treatment
of type 2 diabetes results in improved clinical out-
comes for patients, with treatment guidelines endors-
ing this approach.5–7,9–14 However, patients with type
2 diabetes may not be achieving the multifaceted
targets as part of routine clinical practice.17 The
present analysis, alongside the meta-analysis on which
it is based, provides health care decision makers with
information on how interventions perform in terms of
all round efﬁcacy, rather than focusing on glycemic
control only.
A key aspect to consider with these comparators is
the diabetes treatment algorithm in Canada. Lifestyle
intervention and metformin remain the ﬁrst-line treat-
ment options for patients diagnosed with type 2
diabetes.18 If a patient is not achieving glycemic
control, an individualized treatment decision is
encouraged, taking into account the patient proﬁle
(degree of hyperglycemia, risk of hypoglycemia,
weight, comorbidities, and other preferences) and the
intervention characteristics (blood glucose-lowering
efﬁcacy, risk of inducing hypoglycemia, effect onAugust 2015weight, side effects, and cost). It is likely that sulfo-
nylurea will form the second-line therapy in many
cases, because these are low cost with a proven
HbA1c-lowering effect (despite the associated weight
gain and hypoglycemia). However, intensiﬁcation of
treatment is likely to be required at some stage, either
because of progression of the disease or side effects.
This is often when interventions that target the
incretin axis are prescribed. Two classes of incretin
therapy were developed: glucagonlike peptide-1 re-
ceptor agonists with an extended half-life (such as
liraglutide and exenatide) and dipeptidyl peptidase-4
inhibitors (such as sitagliptin). The present analysis
found that the cost per patient who achieved control is
lower with both liraglutide 1.2 mg and liraglutide
1.8 mg than with alternative therapies that target the
incretin axis (either exenatide or sitagliptin). More-
over, the cost per patient who achieved the composite
clinical end point was lower with liraglutide than with
glimepiride and pioglitazone, therapies generally used
earlier in the diabetes treatment algorithm because of
their low acquisition cost. Liraglutide may represent
the most cost-effective treatment option, from a health
care payer perspective, for patients with type 2
diabetes who do not achieve glycemic control on
metformin monotherapy.
One of the key advantages of the present analysis is
its simplicity and transparency. The analysis does not
rely on long-term cost-effectiveness modeling, as is1685
Clinical Therapeuticscommonly required for economic evaluation of inter-
ventions for type 2 diabetes mellitus.19 Within long-
term analyses, assumptions must be made about
progression of risk factors (such as HbA1c, systolic
blood pressure, serum lipids, and weight) over time
and how these factors affect the likelihood of the
occurrence of the myriad of microvascular and macro-
vascular complications associated with diabetes. As a
result, diabetes models are often complex, and most
cost-effectiveness analyses are run over a long-term
time horizon to adequately capture end-stage compli-
cations. In the present analysis, we sought to offer a
different approach by using a composite end point (in
line with published guidance for Canada) as a surro-
gate for long-term outcomes and a simple modeling
approach with no complex statistical analysis to keep
the assessment of cost-effectiveness transparent. The
results may be salient for a health care payer in
Quebec, or across the Canadian setting. Note, how-
ever, that the cost-of-control concept is not without its
limitations. It does not offer any willingness-to-pay
context (the question of how much is a health care
payer willing to pay per patient who achieved control
is an open one) and fails to offer any generalizability
across analyses or therapeutic areas (as the cost per
quality-adjusted life-year gained approach does).
The results of the present analysis are in agreement
with a previous analysis by using the cost of control
methodology in the US setting, which found that
liraglutide 1.2 mg and 1.8 mg were associated with
a lower cost per patient who achieved HbA1c o7%,
with no weight gain and no hypoglycemic events than
sitagliptin.20 The US analysis was based on a single
study; therefore, it only captured liraglutide and
sitagliptin.21,22 The present study represents the ﬁrst
study to capture the full range of treatment options
available for patients with diabetes who do not
achieve control on metformin monotherapy (which
remains the ﬁrst-line treatment for the condition).
Furthermore, the present study represents the ﬁrst
such assessment in the Canadian setting and, more
speciﬁcally, in Quebec.
Although the simplicity of the present analysis is a
strength because it increased transparency, it may also
be a weakness. The present study captures the cost of
diabetes medications, consumables (such as needles
for injection), and SMBG testing, but it does not
capture costs associated with diabetes-related compli-
cations or the side effects of treatment. As such, the1686overall costs from a health care payer perspective are
underestimated. However, the addition of such costs
would be unlikely to change the outcome in terms of
the relative cost of control with the alternative
interventions because the incidence of costly compli-
cations in the trials included in the meta-analysis was
low, but may have added unnecessary complexity to
the estimation of costs. In addition, over the long
term, bringing patients to treatment targets is likely to
result in improved clinical outcomes through avoid-
ance of long-term complications.
A further limitation of the present study may be
that adherence to the study medications was assumed
to 100% in all treatment groups. Although this has
the potential to lead to an overestimation of pharmacy
costs, in the absence of real-life data on adherence for
the included treatments and the impact of nonadher-
ence on clinical outcomes, it would be difﬁcult to
incorporate adherence into this analysis because it was
not included in the meta-analysis.
The PSA conducted as part of the sensitivity
analyses is subject to a number of limitations. The
meta-analysis on which the present study is based did
not report any measures of uncertainty about the
proportion of patients who achieved control.15
Therefore, to prepare a probabilistic analysis a
number of assumptions had to be made. The
assumptions included maintaining the proportion of
patients who achieved control as a constant in the
liraglutide 1.2 mg arm and sampling the proportion of
patients who achieved control in the other treatment
arms on the basis of sampled odds ratios.
Assumptions were also made when sampling costs.
Despite the limitations and assumptions of the PSA, it
is in line with health economic guidance which states
that parameters should be included in a probabilistic
analysis even if data to inform uncertainty is
lacking.23 Moreover, the PSA provides a useful
insight into the likelihood that each therapy is the
most cost-effective treatment option.
A ﬁnal limitation is that neutral protamine Hage-
dorn insulin is not included in the analysis because it
was not included in the liraglutide trial program.
Neutral protamine Hagedorn insulin represents an
alternative, lower cost basal insulin; however, insulin
glargine is the most widely prescribed basal insulin in
type 2 diabetes and therefore represents the most
suitable basal insulin comparator in the present
analysis.24Volume 37 Number 8
R. Skovgaard et al.CONCLUSIONS
Liraglutide 1.2 mg and 1.8 mg were associated with
lower cost of control values than glimepiride, piogli-
tazone, insulin glargine, sitagliptin, and exenatide, in
the Canadian setting. This was driven by the high
proportion of patients who achieved the composite
end point, which offset the higher drug acquisition
costs.
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